NDAORALSUSPENSION
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
4/8 — Partial
ATMEKSI (methocarbamol) by Baxter is 12. First approved in 2025.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ATMEKSI is an oral muscle relaxant suspension containing methocarbamol, a centrally-acting agent approved for acute musculoskeletal pain relief. The mechanism is presumed to involve CNS depression rather than direct action on muscle fibers. It is rapidly absorbed with a short half-life of approximately 1.3 hours.
Launch18.3 years to LOE
Early-stage launch product with no established Part D spending data; commercial teams should focus on market penetration and physician awareness building.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of methocarbamol in humans has not been established but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber. 12.3…
Worked on ATMEKSI at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.